Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS COMPRISING ESOMEPRAZOLE OR DEXLANSOPRAZOLE AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2024/058527
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating hearing loss comprising esomeprazole or dexlansoprazole as an active ingredient. As the effects of esomeprazole or dexlansoprazole on protecting hair cells from apoptosis caused by cisplatin and inhibiting the uptake of cisplatin by organ cation transporter 2 (OCT2) protein from hair cells, were confirmed, a pharmaceutical composition comprising same as an active ingredient can be used to prevent and treat hearing loss that is a side effect of using cisplatin, which is an anticancer drug.
Inventors:
CHOI JUNE (KR)
LEE INGYUN (KR)
HUR WOOYOUNG (KR)
JEON HANUL (KR)
LEE INGYUN (KR)
HUR WOOYOUNG (KR)
JEON HANUL (KR)
Application Number:
PCT/KR2023/013653
Publication Date:
March 21, 2024
Filing Date:
September 12, 2023
Export Citation:
Assignee:
UNIV KOREA RES & BUS FOUND (KR)
KOREA INST SCI & TECH (KR)
KOREA INST SCI & TECH (KR)
International Classes:
A61K31/4439; A23L33/10; A61K45/06; A61P27/16
Foreign References:
| US20180161340A1 | 2018-06-14 | |||
| US20080242703A1 | 2008-10-02 | |||
| KR20110033295A | 2011-03-30 | |||
| US20150150793A1 | 2015-06-04 |
Other References:
WAKAI ERI, IKEMURA KENJI, MIZUNO TOSHIRO, TAKEUCHI KAZUHIKO, TAMARU SATOSHI, OKUDA MASAHIRO, NISHIMURA YUHEI: "Repositioning of Lansoprazole as a Protective Agent Against Cisplatin-Induced Ototoxicity", FRONTIERS IN PHARMACOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 13, 15 July 2022 (2022-07-15), CH , pages 896760, XP093146218, ISSN: 1663-9812, DOI: 10.3389/fphar.2022.896760
Attorney, Agent or Firm:
TAEBAEK INTELLECTUAL PROPERTY LAW FIRM (KR)
Download PDF: